OTCMKTS:GNMLF Genomma Lab Internacional (GNMLF) Stock Price, News & Analysis $1.43 0.00 (0.00%) As of 03/12/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort Interest About Genomma Lab Internacional Stock (OTCMKTS:GNMLF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GNMLF alerts:Sign Up Key Stats Today's Range$1.43▼$1.4350-Day Range$1.26▼$1.4352-Week Range$0.79▼$1.43VolumeN/AAverage Volume7,289 shsMarket CapitalizationN/AP/E Ratio0.84Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGenomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.Read More… Remove Ads Genomma Lab Internacional Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreGNMLF MarketRank™: Genomma Lab Internacional scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Genomma Lab Internacional. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genomma Lab Internacional is 0.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Genomma Lab Internacional is 0.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.65.Read more about Genomma Lab Internacional's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverGenomma Lab Internacional has a short interest ratio ("days to cover") of 22829, which indicates bearish sentiment.Change versus previous monthShort interest in Genomma Lab Internacional has recently decreased by 16.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenomma Lab Internacional does not currently pay a dividend.Dividend GrowthGenomma Lab Internacional does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverGenomma Lab Internacional has a short interest ratio ("days to cover") of 22829, which indicates bearish sentiment.Change versus previous monthShort interest in Genomma Lab Internacional has recently decreased by 16.18%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentGenomma Lab Internacional has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Genomma Lab Internacional this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genomma Lab Internacional insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 36.55% of the stock of Genomma Lab Internacional is held by institutions.Read more about Genomma Lab Internacional's insider trading history. Receive GNMLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genomma Lab Internacional and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMLF Stock News HeadlinesGENOMMA LAB INTERNACIONAL ANNOUNCES ELEVENTH DIVIDEND PAYMENTMarch 6, 2025 | prnewswire.comGenomma Lab Internacional Announces Results for the Fourth Quarter and Full Year 2024February 26, 2025 | prnewswire.comPlease don’t die on me"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 13, 2025 | Porter & Company (Ad)Genomma Lab Internacional S.A.B. de C.V. Fourth Quarter 2024 Earnings Results Conference CallFebruary 10, 2025 | prnewswire.comGenomma Lab Internacional Announces Results for the Third Quarter 2024October 23, 2024 | prnewswire.comGenomma Lab Internacional S.A.B. de C.V. Third Quarter 2024 Earnings Results Conference CallOctober 4, 2024 | prnewswire.comGENOMMA LAB PHARMA MANUFACTURING FACILITY GRANTED PENDING GMP CERTIFICATION FOR THE MEXICAN MARKETOctober 2, 2024 | prnewswire.comGENOMMA LAB INTERNACIONAL ANNOUNCES NINTH DIVIDEND PAYMENTSeptember 10, 2024 | prnewswire.comSee More Headlines GNMLF Stock Analysis - Frequently Asked Questions How have GNMLF shares performed this year? Genomma Lab Internacional's stock was trading at $1.27 at the start of the year. Since then, GNMLF stock has increased by 12.6% and is now trading at $1.43. View the best growth stocks for 2025 here. How do I buy shares of Genomma Lab Internacional? Shares of GNMLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today3/13/2025Next Earnings (Estimated)4/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:GNMLF CIKN/A Webwww.genommalab.com Phone525550810000FaxN/AEmployees1,614Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.84 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (OTCMKTS:GNMLF) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredPlease don’t die on me"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from ...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genomma Lab Internacional, S.A.B. de C.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genomma Lab Internacional With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.